v3.26.1
Operating Segments (Tables)
 12 Months Ended
Dec. 31, 2025
Operating Segments [Abstract]  
Schedule of Group’s CODM

The Group’s CODM is the CEO of the Company.

 

   Year ended December 31, 2025 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $
-
   $856   $856 
Total   
-
    856    856 
                
Cost of revenues   
-
    225    225 
Research and development expenses   2,097    
-
    2,097 
Sales and marketing   
-
    912    912 
Impairment of intangible assets   
-
    115    115 
General and administrative expenses   6,279    92    6,371 
Other income, net   (490)   
-
    (490)
                
Segment loss   7,886    488    8,374 
Company’s share of losses of company accounted for at equity, net             500 
Gain from sale of an associate             (2,231)
Finance expense, net             5,921 
                
Loss             12,564 
   Year ended December 31, 2024 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $
-
   $1,306   $1,306 
Total   
-
    1,306    1,306 
                
Cost of revenues   
-
    800    800 
Research and development expenses   1,707    
-
    1,707 
Sales and marketing   
-
    1,515    1,515 
Impairment of intangible assets   
-
    1,344    1,344 
General and administrative expenses   4,436    90    4,526 
Other income, net   (1,270)   
-
    (1,270)
                
Segment loss (gain)   4,873    2,443    7,316 
                
Equity losses from the investment in MitoCareX             429 
Finance expense (income), net             (259)
Tax income             (14)
                
 Loss             7,472 

 

   Year ended December 31, 2023 
   Drug
Development		   Online
Sales		   Total 
Revenues            
External  $
-
   $2,879   $2,879 
Total   
-
    2,879    2,879 
                
Cost of revenues   
-
    683    683 
Research and development expenses   1,641    
-
    1,641 
Sales and marketing   
-
    2,484    2,484 
Impairment of intangible assets   
-
    1,042    1,042 
General and administrative expenses   3,718    126    3,844 
Other income, net   
-
    
-
    
-
 
                
Segment loss (gain)   5,359    1,456    6,815 
                
Company’s share of losses of company accounted for at equity, net             210 
Finance expense (income), net             (1,164)
Tax expense             22 
                
Loss             5,883 
   As of December 31, 2025 
   Drug
Development		   Online
Sales		   Total 
             
Segment assets  $6,224   $1,398   $7,622 
Segment liabilities  $2,213   $262   $2,475 

 

   As of December 31, 2024 
   Drug
Development		   Online
Sales		   Total 
             
Segment assets  $8,407   $1,764   $10,171 
Segment liabilities  $1,194   $226   $1,420